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Background: Bioartificial liver systems, designed to support patients with liver failure,
are composed of bioreactors and functional hepatocytes. Immunological rejection of
the embedded hepatocytes by the host immune system is a serious concern that
crucially degrades the performance of the device. Induced pluripotent stem (iPS) cells
are considered a desirable source for bioartificial liver systems, because patient-derived
iPS cells are free from immunological rejection. The purpose of this paper was to test
the feasibility of a bioartificial liver system with iPS cell-derived hepatocyte-like cells.
Methods: Mouse iPS cells were differentiated into hepatocyte-like cells by a multi-step
differentiation protocol via embryoid bodies and definitive endoderm. Differentiation of
iPS cells was evaluated by morphology, PCR assay, and functional assays. iPS
cell-derived hepatocyte-like cells were cultured in a bioreactor module with a pore size
of 0.2 μm for 7 days. The amount of albumin secreted into the circulating medium was
analyzed by ELISA. Additionally, after a 7-day culture in a bioreactor module, cells were
observed by a scanning electron microscope.
Results: At the final stage of the differentiation program, iPS cells changed their
morphology to a polygonal shape with two nucleoli and enriched cytoplasmic
granules. Transmission electron microscope analysis revealed their polygonal shape,
glycogen deposition in the cytoplasm, microvilli on their surfaces, and a duct-like
arrangement. PCR analysis showed increased expression of albumin mRNA over the
course of the differentiation program. Albumin and urea production was also observed.
iPS-Heps culture in bioreactor modules showed the accumulation of albumin in the
medium for up to 7 days. Scanning electron microscopy revealed the attachment of
cell clusters to the hollow fibers of the module. These results indicated that iPS cells
were differentiated into hepatocyte-like cells after culture for 7 days in a bioreactor
module with a pore size of 0.2 μm.
Conclusion: We consider the combination of a bioreactor module with a 0.2-μm pore
membrane and embedded hepatocytes differentiated from iPS cells to be a promising
option for bioartificial liver systems. This paper provides the basic concept and
preliminary data for an iPS cell-oriented bioartificial liver system.
PACS code: 87. Biological and medical physics, 87.85.-d Biomedical engineering, 87.85.Lf
Tissue engineering, 87.85.Tu Modeling biomedical systems.
Keywords: Induced pluripotent stem cells, Bioartificial liver system, Hepatocyte
differentiation, Hollow fiber bioreactor, Antibody-mediated rejection© 2012 Iwamuro et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
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Non-biological artificial liver systems are external supportive devices that are currently
applied to patients with liver dysfunction. The basic mechanism of a non-biological
artificial liver system is albumin dialysis, and the two representative devices include
extracorporeal albumin dialysis (MARSW) and fractionated plasma separation and
absorption (PrometheusW). Improvement of jaundice, hepatic encephalopathy, systemic
hemodynamic dysfunction and/or portal hypertension has been observed by these sys-
tems [1,2]. However, these outcomes are temporary, and randomized control trials have
failed to show clear a benefit of such systems to the long-term survival of these patients
[3-7]. In theory, an ideal artificial liver system could permanently replace liver func-
tions, providing most or even all normal liver functions such as detoxification and syn-
thesis [8,9]. To achieve replacement of whole liver function, investigators have tried to
develop cell-based external artificial biological devices, namely, a bioartificial liver
(BAL) system.
A bioartificial liver (BAL) system is composed of bioreactors and embedded hepato-
cytes that provide protein synthesis, ureogenesis, ureagenesis and glucogenesis, and de-
toxification through P450 activity [8,10,11]. Various cell types, such as primary human
hepatocytes, immortalized cell lines of C3A human hepatoblastoma cells, and cryopre-
served porcine hepatocytes have been studied for BAL applications. Several studies of
BAL use have been reported as clinical trials [12-15], although none of these BAL sys-
tems has yet been approved by the FDA. Major problems of BAL systems include insuf-
ficient supply of functional hepatocytes, premature death of hepatocytes by immune
mechanisms, and the inadequate performance of devices for mass transfer [16].
Induced pluripotent stem (iPS) cells are artificially derived stem cells that have been
genetically reprogrammed to an embryonic stem cell-like state. iPS cells were first
created in 2006 from mouse fibroblasts and in 2007 from human fibroblasts by forced
expression of specific genes [17-19]. iPS cells are pluripotent and are able to proliferate
unlimitedly in vitro. This technical breakthrough in creating iPS cells from somatic
cells has noteworthy implications for producing large amounts of iPS cell-derived func-
tional hepatocytes that could overcome immunological rejection. In this context, iPS
cells are expected as one of the favorable cell sources for cell therapy. The purpose of
this paper is to test the feasibility of a BAL system with iPS cell-derived hepatocytes.
The optimal pore size for BAL devices is also investigated.Methods
Culture of undifferentiated mouse iPS Cells
Mouse iPS cells were purchased from Riken Cell Bank (Cell No. APS0001, Cell name
iPS-MEF-Ng-20D-17, Lot No. 006) [20]. Mouse iPS cells of 11–20 passages were main-
tained by culture on a feeder layer of mouse embryo fibroblasts (MEF) (Dainippon
Pharmaceutical, Osaka, Japan) inactivated by mitomycin C (Biomol, Enzo Life Sciences
International, PA) on gelatin (Specialty Media, Chemicon International, MA)-coated
plates. iPS cells were cultured with Complete ES cell medium (Specialty Media, Chemicon
International) supplemented with 1000 U/ml recombinant leukemia inhibitory factor (LIF)
(ESGRO, Chemicon International) at 37°C in 5% CO2. Each passage was carried out before
cells reached confluency [21].
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Differentiation was carried out in four stages as described previously, with minor
modification [22].
Stage 1: Formation of Embryoid Bodies (Days 0–1). iPS cells growing on feeder cells
were dispersed by treatment with trypsin-EDTA (Sigma-Aldrich Japan, Tokyo, Japan)
and collected by centrifugation at 800 rpm for 3 min. Cells were then resuspended in
Knockout DMEM (Gibco, Invitrogen, CA) supplemented with 15% knockout serum
replacement (KSR) (Gibco), 1% nonessential amino acids (MP Biomedicals, CA),
1% 2-mercaptoethanol (Gibco), 1% penicillin/streptomycin (Sigma-Aldrich Japan),
and 1% l-glutamic acid (DS Pharma Biomedical, Osaka, Japan). The iPS cells were
then transferred to ultra-low-attachment six-well plates (Corning, NY) and were cul-
tured free floating in the culture medium at a density of 2 × 105 cells/2 ml/well to
induce the formation of embryoid bodies (at day 0). Half of the medium was
replaced daily.
Stage 2: Induction of Definitive Endoderm (Days 2–4). At day 2, embryoid bodies
were collected from the single well and centrifuged at 1000 rpm for 3 min. Embryoid
bodies were then resuspended in 9 ml of Knockout DMEM, 1% penicillin/streptomycin,
1% l-glutamic acid, 100 ng/ml activin A (R&D Systems, MN), and 100 ng/ml basic
fibroblast growth factor (FGF) (Peprotech, NJ) to induce a definitive endoderm. In each
well of a gelatin-coated 12-well plate, 1.5 ml of the medium containing embryoid
bodies was seeded. Embryoid bodies were cultured for an additional 3 days. KSR was
supplemented at days 3–4 and the concentrations were varied: 0.2% for day 3 and 2.0%
for day 4. Half of the medium was replaced daily.
>Stage 3: Differentiation of Premature Hepatocyte-Like Cells (Days 5–11). At day 5,
the medium was replaced by Knockout DMEM supplemented with 1% KSR, 1% nones-
sential amino acids, 1% l-glutamic acid, 1% dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
Irvine, UK), and 100 ng/ml hepatocyte growth factor (HGF) (Peprotech, NJ) to induce
premature hepatocyte-like cells. The medium was replaced every two days.
Stage 4: Differentiation of Matured Hepatocyte-Like Cells (Days 12–18). At day 12,
the medium was replaced by Knockout DMEM supplemented with 1% KSR, 1% nones-
sential amino acids, 1% l-glutamic acid, and 40 ng/ml dexamethasone (Sigma-Aldrich)
to induce hepatocyte-like cells (iPS-Heps). The medium was replaced every two days.
The differentiation program was finished at day 19.Characterization of differentiated hepatocyte-like cells by imaging modalities
Phase-contrast images were observed by CKX41 phase-contrast microscopy (Olympus,
Tokyo, Japan). Periodic acid Schiff (PAS) analysis was performed with PAS staining
solution (Muto Pure Chemicals, Tokyo, Japan), according to the manufacturer’s instruc-
tions. Briefly, the cultured cells were fixed in 3.3% formalin for 10 min, and intracellular
glycogen was stained using a PAS staining solution. For transmission electron micro-
scope analysis, samples were fixed using 2% paraformaldehyde and 2% glutaraldehyde
in 0.1 mol/L phosphate buffer solution at 4°C for 18 h. The samples were then post-
fixed with 2% OsO4 and dehydrated by ethanol before being embedded in epoxy resin.
Ultra-thin sections were examined under an H-7100 transmission electron microscope
(Hitachi, Tokyo, Japan).
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Reverse-transcription polymerase chain reaction (RT-PCR) was carried out at various
points of the differentiation program to determine the degree to which iPS cells differ-
entiated toward iPS-Heps. RNA was extracted using an RNeasy Mini Kit (QIAGEN,
Duesseldorf, Germany) according to the manufacturer’s instructions. Complementary
DNA was prepared using MuLV reverse transcriptase (Applied Biosystems, CA) and
RNase inhibitor (Applied Biosystems) from 2 μg of total RNA. RT-PCR was performed
with TaKaRa LA Taq DNA polymerase (Takara Bio Inc., Otsu, Japan). Primers used for
RT-PCR are listed in Table 1. PCR products were resolved on 2% agarose gels and
visualized by ethidium bromide staining. Real-time PCR was performed on a LightCy-
cler 1.5 Instrument (Roche Applied Science, IN) with LightCycler FastStart DNA mas-
ter SYBR green I (Roche Applied Science, IN) according to the manufacturer’s
instructions. Primers are listed in Table 2.Hepatocyte isolation
Normal primary hepatocytes were prepared as positive controls for PCR analysis and
ELISA assay. Mouse hepatocytes were isolated from the whole liver of an adult C57BL/
6 mouse (male, 8–12 weeks old) by the two-step liver perfusion method [23] with the
commercially available liver perfusion medium, liver digest medium, and hepatocyte
wash medium (Life Technologies, CA). Cell viability was determined by trypan blue ex-
clusion, and cells obtained with more than 60% viability were plated on collagen-I
coated dishes (Iwaki, Tokyo, Japan). Isolated hepatocytes were maintained with
HepatoZYME-SFM medium (Life Technologies) for 24 hours, and then the cells and
the medium were collected.Measurement of albumin production by ELISA
The supernatant of the mouse iPS cell culture was collected. The amount of albumin
secreted into the culture medium was measured by an albumin enzyme-linked-
immunosorbent assay (ELISA) kit (Immunology Consultants Laboratory, OR), as per
the manufacturer’s instructions.Evaluation of permeability of albumin and IgG in bioreactor modules with different pore
sizes
To test the permeability of albumin and IgG in bioreactor modules, a CellMax hollow
fiber bioreactor system (Spectrum Laboratories Inc., CA) and a polysulfone membrane
cartridge with 145 cm2-surface area and pore sizes of 100 kilodaltons, 500 kilodaltons,Table 1 RT-PCR primers used in the present study
Gene Forward Primer Reverse Primer Product Size (bp)
AFP CACTGCTGCAACTCTTCGTA CTTTGGACCCTCTTCTGTGA 300
Alb GACAAGGAAAGCTGCCTGAC TTCTGCAAAGTCAGCATTGG 174
Trf ACCATGTTGTGGTCTCACGA ACAGAAGGTCCTTGGTGGTG 135
CPS AGGATGTCAAGGTGTTTGGC GCTTAACTAGCAGGCGGATG 93
β-actin GACCTCTATGCCAACACAGT AGTACTTGCGCTCAGGAGGA 139
AFP, α-fetoprotein; Alb, Albumin; Trf, transferrin; CPS, carbamoyl phosphate synthetase.
Table 2 Real-Time RT-PCR primers used in the present study
Gene Forward Primer Reverse Primer Product Size (bp)
AFP AAACATCCCACTTCCAGCAC AGCGAAATGTAGCAGGAGGA 94
Alb GTTCGCTACACCCAGAAAGC CCACACAAGGCAGTCTCTGA 124
Trf ACCATGTTGTGGTCTCACGA ACAGAAGGTCCTTGGTGGTG 135
CPS AGGATGTCAAGGTGTTTGGC GCTTAACTAGCAGGCGGATG 93
β-actin GACCTCTATGCCAACACAGT AGTACTTGCGCTCAGGAGGA 139
AFP, α-fetoprotein; Alb, Albumin; Trf, transferrin; CPS, carbamoyl phosphate synthetase.
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lary space of the cartridge was perfused with 200 ml of perfusion medium at the slowest
flow rate of the system. The perfusion medium consisted of Knockout DMEM supple-
mented with 1% KSR, 1% nonessential amino acids, 1% l-glutamic acid, and 40 ng/ml
dexamethasone. After the injection of 20 μg of mouse albumin or 2 μg of mouse IgG
resuspended with 5 mL of perfusion medium into the extracapillary space, the drained
medium from the intracapillary space was collected at 0, 30, 60, 90, 120, 150, and 180
min. The amount of permeated albumin and IgG was measured by a mouse albumin
ELISA kit and mouse IgG ELISA kit (Immunology Consultants Laboratory), according
to the manufacturer’s instructions.Culture of iPS-Heps and isolated hepatocytes in a bioreactor module
The culture of iPS-Heps in a bioreactor module was carried out by a CellMax hollow
fiber bioreactor system and a polysulfone membrane cartridge with a 145-cm2 surface
area and 0.2-μm pores. Prior to the injection of iPS-derived premature hepatocyte-like
cells, the system was perfused with 200 ml of perfusion medium as described above.
Cells at the end of stage 3 (day 12) of differentiation were collected from two 12-well
plates and centrifuged at 1000 rpm for 3 min. Cells were then resuspended in 2 ml of
perfusion medium and were injected into the extracapillary space of the bioreactor
module. Cells were incubated at 37°C in 5% CO2 for up to 7 days at the slowest flow
rate of the system. The medium was not replaced during the period of incubation. The
culture of isolated mouse hepatocytes was performed by the same system with 5.0 × 105
hepatocytes with 200 ml of HepatoZYME-SFM medium.
To monitor the amount of albumin secreted into the intracapillary space, medium
was collected every 24 hours. The concentration of urea was also measured by SRL,
Inc. (Tokyo, Japan) after the 7-day culture.Scanning electron microscope analysis
After the 7-day culture of iPS-Heps in a bioreactor module, the cartridge was dis-
mantled and hollow fibers were brought out. The hollow fibers were immersed for 8 h
in a mixture of 2% paraformaldehyde and 2% glutaraldehyde in 0.1 mol/L phosphate
buffer solution (pH 7.4). The samples were washed twice in phosphate buffer solution
for 1 h each and postfixed for 2 h in 1% OsO4 in phosphate buffer. Samples were rinsed
for 1 h in phosphate buffer and dehydrated in an ascending ethanol series (50, 70, 90,
95, and 99.5%; 20 min each) before 1 h of drying with tert-butyl alcohol. The polished
surface coated with osmium (HPC-1S type osmium coater; Shinku Device Co. Ltd.,
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(Hitachi).Results
After 19 days of the differentiation program, the cells had a polygonal shape with two
nucleoli and enriched cytoplasmic granules (Figure 1A,B). Glycogen storage was con-
firmed by PAS staining (Figure 1C). Transmission electron microscope analysis also
demonstrated that the polygonal cells had glycogen deposition in the cytoplasm,
namely, glycogen fields (Figure 1D,E). Differentiated cells partly formed duct-like struc-
tures, and the cells had many microvilli projecting into the intercellular space
(Figure 1F). These morphological characteristics were compatible with those of normal
mouse hepatocytes in culture.
RT-PCR analysis showed that the expression of albumin, a marker for mature hepato-
cytes, progressively increased over the course of the differentiation program
(Figure 2A,B). Albumin production in the culture media was also observed by ELISA
assay. At day 19, the amount of albumin produced by differentiated cells was 6.45 ±
0.78 ng/24h/105 cells (Figure 2C). Gene expression levels of hepatocyte-enriched mar-
kers, such as the urea cycle enzyme carbamoyl phosphate synthetase and transferrin
also intensified in a time-dependent manner. The result confirmed progressive differen-
tiation toward hepatocytes in the population of cells. However, the expression level of
iPS-Heps was much lower than that of isolated hepatocytes. Moreover, α-fetoprotein
expression, which is present in the endoderm but is not expressed by mature hepato-
cytes, was still detected after 19 days of differentiation. These gene expression profiles
indicate that the final products of our differentiation program were not fully matured
hepatocytes.
Albumin is the main protein of blood plasma and is produced in the liver. Albumin
serves as a carrier for molecules of low water solubility, including several toxic substancesFigure 1 Morphological evaluation of differentiated iPS cells. Differentiated iPS cells (day 19) had a
polygonal shape with two nucleoli and enriched cytoplasmic granules (A,B). PAS staining demonstrated
intracellular deposition of glycogen (C). Transmission electron microscopy revealed their polygonal shape
and glycogen deposition in the cytoplasm (D,E). Differentiated cells partly formed duct-like structures with
microvilli on the cell surface which projected into the intercellular space (F). These morphological
characteristics resembled those of normal mouse hepatocytes in culture. Scale bar = 1 μm.
Figure 2 Functional analysis of iPS cell-derived hepatocyte-like cells. RT-PCR analysis showed
progressive increase of mRNA expression of hepatocyte-enriched markers, such as albumin, the urea cycle
enzyme carbamoyl phosphate synthetase, and transferrin over the course of differentiation program (A,B).
However, gene expression levels of such markers in differentiated iPS cells (day 19) were much lower
than those of isolated hepatocytes. Moreover, strong expression of α-fetoprotein at day 19 indicated that
the final product of the differentiation program was not fully matured hepatocytes. Real-time PCR
analysis of gene expression levels relative to β actin was performed using three independent
experiments. *p < 0.01 iPS cells vs differentiated cells (day 19). †p < 0.01 differentiated cells (day 2) vs
differentiated cells (day 19). ‡p < 0.01 differentiated cells (day 5) vs differentiated cells (day 19). §p < 0.01
differentiated cells (day 12) vs differentiated cells (day 19). An ELISA assay showed that the amount of
albumin produced by differentiated cells (day 19) was 6.45 ± 0.78 ng/24h/105 cells (C). *p < 0.01 iPS cells
vs differentiated cells (day 12). †p < 0.01 iPS cells vs differentiated cells (day 19). ‡p < 0.01 differentiated
cells (day 12) vs differentiated cells (day 19). The ELISA data shown are means ± SDs from three
independent experiments.
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zone, clofibrate, and phenytoin). On the other hand, IgG is one of the immunoglobulins
that initiate antibody-mediated immune responses. Accordingly, a membrane that permits
albumin permeation and blocks IgG permeation is favorable for a BAL device. Theoretic-
ally, a pore membrane of 100 kilodaltons would satisfy this condition, because the pore
size is larger than the molecular weight of albumin (67 kilodaltons) and is smaller
than IgG (147 kilodaltons). However, the permeability assay in this study revealed that
neither albumin nor IgG could pass though membrane with 100-kilodalton pores,
whereas both albumin and IgG permeated cartridges of 500-kilodalton pores or
0.2-μm pores (Figure 3). These results were in concordance with those reported by
other authors [24]. Consequently, it does not seem feasible to separate albumin and
IgG by filtration with a specific pore size. Based on this reasoning, we concluded that
it is impossible to construct the BAL system with isolated hepatocytes that have both
a sufficient supply of proteins and an immunological barrier. In this context, iPS cell-
derived hepatocytes are the most adequate cell source for constructing such ideal BALs.
Figure 3 Result of permeability assay of membranes with three different pore sizes. The permeability
assay in this study revealed that neither albumin nor IgG could pass through a membrane with
100-kilodalton pores, whereas both albumin and IgG permeated membranes with 500-kilodalton pores and
0.2-μm pores. None of the three membranes (100-kilodalton, 500-kilodalton, or 0.2-μm pores) could
separate albumin and IgG. *p < 0.01 membranes with 500-kilodalton pores vs 100-kilodalton pores.
†p < 0.01 membranes with 0.2-μm pores vs 100-kilodalton pores. The data shown are means ± SDs from
three independent experiments.
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tion of produced albumin in the medium over the culture period (Figure 4A). Ulti-
mately, the production of albumin by iPS-Heps was 82.4 ± 12.7 ng/ml. On the other
hand, isolated hepatocytes in the bioreactor modules produced a significant amount of
albumin on day 1 (141.1 ± 21.3 ng/ml). However the amount was only slightly increasedFigure 4 Culture of iPS-Heps in bioreactor modules. An ELISA assay showed a linear increase in
albumin for 7 days in bioreactor modules embedding iPS-Heps (A). The amount of albumin produced by
iPS-Heps in the bioreactor module at day 7 was 82.4 ± 12.7 ng/ml. Isolated hepatocytes in the bioreactor
modules produced a significant amount of albumin on day 1 (141.1 ± 21.3 ng/ml) The amount had only
slightly increased by day 3, then the albumin concentration sequentially decreased over the following 4
days. The ELISA data shown are means ± SDs from three independent experiments. *p < 0.01 iPS cells vs
isolated hepatocytes. iPS-Heps produced urea at the concentration of 0.1 ± 0.1 mg/dl, whereas hepatocytes
produced 0.6 ± 0.1 mg/dl (B). *p < 0.01 iPS cells vs isolated hepatocytes. †p < 0.01 iPS-Heps vs isolated
hepatocytes. Scanning electron microscopy analysis showed cell clusters attached to the extracapillary
membrane (C,D,E). These results indicated that iPS-Heps existed in the extracapillary space in an adhesive
state, and those cells survived for up to 7 days of culture. Scale bar = 10 μm.
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days. We speculated that the change in albumin concentration resulted from apoptosis
of isolated hepatocytes and degeneration of the albumin protein itself. Urea production
was also confirmed after 7-day culture of iPS-Heps in the bioreactor modules, suggest-
ing the detoxication potential of ammonia via the urea cycle. However the amount of
urea produced by iPS-Heps (0.1 ± 0.1 mg/dl) was much smaller than that produced by
hepatocytes (0.6 ± 0.1 mg/dl).
Cell clusters attached to the extracapillary membrane were observed by scanning
electron microscope (Figure 4C,D,E). These results indicated that iPS-Heps existed in
the extracapillary space in an adhesive state, and those cells survived for up to 7 days
of culture. Moreover, maturation of iPS cells into albumin-producing cells could be car-
ried out in hollow fiber modules.Discussion
Transplant rejection, which can lead to early graft damage and loss, is a major problem in
the field of transplantation medicine. Transplant rejection is caused by two mechanisms:
antibody-mediated rejection and T cell-mediated rejection. Among these, antibody-
mediated rejection is the more common cause of hyperacute rejection and chronic rejec-
tion. Pre-existing donor-specific antibodies can be generated by previous exposure to major
histocompatibility antigens via blood transfusions, previous allografts or pregnancy. Such
antibodies destroy transplanted tissue; therefore, patients present with immediate graft dys-
function [25,26]. On the other hand, de novo donor-specific antibodies that develop after
transplantation are capable of triggering insidious graft injury in the late phase of post-
transplantation. Protection against hyperacute rejection and chronic rejection are vital to
BAL systems [27,28], as well as to organ transplantation and to cell transplantation [29].
Nyberg et al. tested a membrane with 0.2-μm pores and one with 400-kilodalton
pores [10]. They observed more dead hepatocytes in the 0.2-μm pore group than in the
400-kilodalton pore group, with positive deposition of host IgG, IgM, and complements
among the dead hepatocytes. Additionally, the cytotoxicity was reduced by heating the
host serum for 30 min at 56°C, conditions known to denature the complement. Xhi
et al. and Zhang et al. also reported similar results using a 200-kilodalton pore mem-
brane and a 1200-kilodalton pore membrane [30,31]. Their results suggested that
antibody-mediated immune responses involving complement systems occurred in a
BAL system with a larger pore size. Accordingly, the use of a membrane with a smaller
pore size has protective advantage from antibody-mediated rejection.
Another concern for BAL systems is the mass transfer efficiency of bioreactor
devices. Principally, key functions of a BAL system, such as supply of synthesized pro-
tein to the host, detoxification, ureogenesis, ureagenesis and glucogenesis, are regulated
by mass transfer through the membrane of the devices. Mass transfer rates are mainly
determined by membrane permeability [24,30]. Larger pore size enables more efficient
exchange of substances via the membrane of the module [28]. Conversely, a membrane
with a large pore size may permit permeation of immunoglobulins that can cause
antibody-mediated rejection of embedded hepatocytes.
In theory, a membrane with a smaller pore size than the molecular weight of immu-
noglobulins, e.g., IgG (147 kilodaltons), IgM (900 kilodaltons) and IgE (190 kilodaltons),
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through a membrane with 100-kilodalton pores. This membrane pore size is larger than
the molecular weight of representative substances metabolized by hepatocytes, such as
albumin (67 kilodaltons), conjugated bilirubin (0.760 kilodalton), unconjugated biliru-
bin (0.585 kilodalton), and ammonia (0.017 kilodalton). However, albumin was not
detected in the intracapillary flow even after circulation of medium for 180 min. Nedredal
et al. reported similar results as ours: they investigated the mass transfer effect of hollow
fiber modules with 70-, 150-, and 400-kilodalton pore sizes, and noted that albumin did
not pass through the 70-kilodalton pore membrane, but did through the 150- and 400-
kilodalton pore membranes [24]. We speculate that membrane fouling, due to albumin
itself or materials in the circulating medium, caused the inhibition of albumin permeation.
Nedredal et al. reported that a 70-kilodalton membrane showed a 62.5% reduction of
permeability within 20 min after flushing of polydispersed dextran solution [24]. Lesser
reduction rates were shown in the 150-kilodalton membrane (23.7%) and 400-kilodalton
membrane (7.1%). These data indicate that exposure of a smaller-pore membrane to the
medium or plasma can cause serious blockage of the pores. Thus, it seems impractical to
construct an ideal BAL system, which would enable both efficient mass transfer and
complete blockage of antibodies.
iPS cell-derived hepatocytes have great advantages over other cell sources for BAL
systems, such as primary human hepatocytes, immortalized cell lines of C3A human
hepatoblastoma cells, and cryopreserved porcine hepatocytes. Autotransplantation
of hepatocytes differentiated from a patient’s own iPS cells is free from the issue of
immunological rejection. Therefore, a membrane with the largest pore size can be
employed for a BAL system with iPS cell-derived hepatocytes because blockage of
immunoglobulins is not required. Obviously, the largest pore size for such a BAL sys-
tem would allow a maximal mass transfer rate without membrane fouling. In this study,
we applied hollow fiber modules with a 0.2-μm pore for iPS-Heps culture. iPS-Heps
infused into the extracapillary space adhered to the surface of hollow fibers, and those
cells were successfully cultured for 7 days. Consistent increase of the albumin concen-
tration in the intracapillary flow indicated that iPS-Heps were functional during the
culture period. In addition, albumin transfer via the membrane was operative for 7 days,
without significant reduction of permeability. These data suggest that the combination
of a 0.2-μm pore membrane and iPS cell-derived hepatocytes is a good candidate for an
improved BAL system.
Unlimited proliferation is another advantage of iPS cells, whereas primary hepatocytes
have knotty problems including limited supply, low viability after cryopreservation,
prompt in vitro degeneration, and poor proliferative ability [2]. However, there are
several obstacles to be overcome for iPS cell-oriented regenerative therapies. So far, dif-
ferentiation of iPS cells into fully matured hepatocytes is hard to achieve. Even with
modification of the differentiation protocol, complete differentiation of iPS cells in vitro
has not yet been reported [8]. In a recent report, Yu et al. noted that iPS cell-derived
hepatocytes also expressed high levels of alpha fetoprotein even by means of an
improved protocol under a low oxygen condition, suggesting a persistent immature
phenotype or an incapability to turn off early-stage genes [32]. Similarly, the final pro-
duct of the differentiation program in this study showed much lower metabolic function
compared with isolated hepatocytes. Thus, establishment of a differentiation protocol to
Iwamuro et al. BioMedical Engineering OnLine 2012, 11:93 Page 11 of 12
http://www.biomedical-engineering-online.com/content/11/1/93generate fully matured hepatocytes should be given the highest priority to realize a BAL
system with iPS cell-derived hepatocytes. A possible approach to achieve this goal is to
differentiate iPS cells in an in vivo environment or coculture them with a combination
of liver-populating cells [33]. High cost is another concern for iPS cell-oriented cell the-
rapy, because expanding and differentiating iPS cells requires expensive reagents. Al-
though such problems are still to be resolved before the clinical application of iPS cells,
we believe that iPS cells should enable the production of patient-specific donor cells in
the near future.Conclusions
In summary, we tested a BAL system embedded with iPS cells. iPS-Heps were injected
into a module with a 0.2-μm pore membrane. Those cells adhered to the surface of
hollow fibers and produced albumin and urea at least for 7 days. Although further
investigation and improvement of both the devices and the differentiation program is
required, we can conclude that the combination of a 0.2-μm pore membrane and iPS
cell-derived hepatocytes shows promise for an improved BAL system. This paper pro-
vides the basic concept and preliminary data for an iPS cell-oriented BAL system.Competing interests
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